Accelerate to discover

Back to filter

Related topics

Imaging Flow Cytometry Luminex learning sessions

Luminex

Mar 5, 2021

Start the new year with new knowledge! Get the most from your Amnis instrument and IDEAS Software with training...

Preclinical lung imaging offers effective evaluation of drug candidates

Bruker Biospin

Mar 1, 2021

The incidence of respiratory disease is increasing throughout the world, and the demand for safe, effective drugs to...

Online courses on Stroke, Diabetes, VCID research

RWD

Feb 18, 2021

Are you interested in research of Stroke, Diabetes, or VCID Research? Do you want to share your knowledge with other...

Curiox Laminar Wash technology to become a gold standard for TotalSeq Protocol.

Curiox

Feb 15, 2021

Curiox Laminar Wash technology has been added as part of the official BioLegend TotalSeq Protocol. It makes processing...

Mar 7, 2021

Amnis CellStream's new software features - now better than ever

Luminex

Feb 12, 2021

It's finally here, and better than ever - Amnis CellStream's Acquisition and Analysis Software update increases ease of...

The function of LSCI with off Line Model

RWD

Feb 10, 2021

In this video, we will show you how to change the pseudo-color off-line. At the same time, we will show you how to...

Towards silent and distortion-free fMRI with Zero Echo Time MRI

Bruker Biospin

Feb 9, 2021

By using fast imaging techniques capable of scanning large brain regions within short durations, continuous snapshots...

Mar 7, 2021

Cytek Aurora in Action : how to easily resolve highly overlapping dyes ?

Cytek Biosciences

Feb 2, 2021

Learn from Jeff Nelson, a manager of a cytometry shared resource laboratory, about the Cytek Aurora's unique features...

Show all topics (10)

Heterodimeric compounds with dual-targeting active against both HIV and tuberculosis.

Jun 4, 2018

Both HIV and Tuberculosis are considered to be one of the most dangerous infectious diseases in the world. Quite often these two pathogens work in synchrony, making the risk of patient´s death twice as high. To solve this problem researchers from the Engelhardt Institute of Molecular biology in Russia cooperated with the National Institute of Health in the USA. They created compounds with dual activity against both pathogens by creating a heterodimer based on nucleosides. These heterodimers have two active components with two different rates of release based on the speed of their hydrolysis. They tested five of such compounds on HIV and Tuberculosis strain MS-114, which is drug-resistance. Drug-resistance of tuberculosis is one of the main problems in the treatment nowadays.

The compounds were judged based on the ability to inhibit these pathogens. Additionally, a testing on the host tissue was done using NovoCyte. The researchers tested the viability of mammalian lymphoid tissue after treatment. The results show that the heterodimers are non-toxic and non-static towards the cells while maintaining the potency against the pathogens. So far the compound was tested in vivo and ex vitro and seem to be a very promising solution. These results bring interesting insight and novel approach toward treatment of both HIV and Tuberculosis.

Want to know more?

Scientific paper
Application

Related technologies: Conventional flow cytometry

Brand profile

Agilent technologies

Agilent provides xCELLigence impedance-based, label-free, real time cell analysis system and NovoCyte flow cytometers.

Related products

The best in class personalized flow cytometer

show detail

We supply and support Life-Science Technologies in the territory of Central and Eastern Europe.

Czech Republic

Slovakia

Hungary

Poland

Croatia

Slovenia

Serbia

Romania

Bulgaria

Latvia

Lithuania

Estonia

Russia

Ukraine

Belarus

Turkey